A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN <i>FGFR1</i>)
Jason Gotlib(Stanford University), Srđan Verstovšek(The University of Texas MD Anderson Cancer Center), Andreas Reiter(Heidelberg University), Hui‐Ling Zhen(Incyte (United States)), Jay Patel(Memorial Sloan Kettering Cancer Center), Alessandro M. Vannucchi(University of Florence), Jean‐Jacques Kiladjian(Assistance Publique – Hôpitaux de Paris), Philomena Colucci(Incyte (United States)), William Shomali(Stanford Medicine), Chris Walker(Incyte (United States)), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Tracy I. George(University of Utah)
Cited by 51
Related Papers
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k